scholarly journals Once daily Long-acting beta2 -agonists/Inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease

2016 ◽  
Author(s):  
Agnieszka Sliwka ◽  
Milosz Jankowski ◽  
Iwona Gross-Sondej ◽  
Roman Nowobilski ◽  
Malgorzata M Bala
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Inhaled Corticosteroids ◽  
Chronic Obstructive ◽  
Muscarinic Antagonists ◽  
Obstructive Pulmonary Disease ◽  
Once Daily ◽  
Long Acting

Effect of chronic obstructive pulmonary disease treatment on cardiovascular outcome

ESC CardioMed ◽  
2018 ◽  
pp. 1050-1053
Author(s):  
Jennifer Quint
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Inhaled Corticosteroids ◽  
Systemic Disease ◽  
Chronic Obstructive ◽  
Muscarinic Antagonists ◽  
Obstructive Pulmonary Disease ◽  
Beta Agonists ◽  
The People ◽  
Long Acting

The mainstay of pharmacological treatment of chronic obstructive pulmonary disease (COPD) treatment is inhalers, consisting of bronchodilators, both long-acting muscarinic antagonists and long-acting beta agonists, and inhaled corticosteroids. While the muscarinic antagonists and beta agonists act to open up the airways and have bronchodilating effects on smooth muscle thus decreasing breathlessness, inhaled corticosteroids dampen down the inflammatory process. COPD is considered a systemic disease and is associated with cardiovascular co-morbidities, but people with COPD who have cardiovascular disease (CVD) are often the very patients who are excluded from participating in randomized controlled trials of these medications thus making ascertainment of the true relationship between CVD and COPD treatments difficult. Trials suggest that long-acting muscarinic antagonists and long-acting beta agonists are safe when used in appropriate doses in people with COPD who do not have uncontrolled CVD, but in patients with underlying CVD or who use higher doses or more pharmacologically active medications the implications are less clear. Some people would argue that the data that currently exist from trials are not representative of real life and the long-term safety of COPD treatments is not known in the people in whom it matters most.

Current opportunities of inhaled corticosteroid therapy in patients with chronic obstructive pulmonary disease

2021 ◽  
Vol 31 (1) ◽  
pp. 75-87
Author(s):  
I. V. Leshchenko ◽  
A. S. Meshcheryakova
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Inhaled Corticosteroids ◽  
Fixed Combination ◽  
Chronic Obstructive ◽  
Delivery Device ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Long Acting ◽  
Blood Eosinophils

Chronic obstructive pulmonary disease (COPD) is the leading cause of death in the structure of respiratory diseases. The problem of rational pharmacotherapy of COPD have attracted attention of the medical scientific society for many years. The understanding of the pathogenesis of the disease has deepened and approaches to the therapy have changed. Some COPD patients need regular fixed-combination therapy: long-acting bronchodilators (LABD) and inhaled corticosteroids (ICS) in order to prevent exacerbations and reduce the severity of symptoms of the disease. Blood eosinophils count is one of criteria for choosing regular therapy. The appearance of fixed triple combinations of ICS/LABD increased the effectiveness of COPD therapy, and a new delivery device for fixed combination of budesonide/formoterol makes it possible to use ICS successfully in the most severe patients.

Sign in / Sign up

Export Citation Format

Share Document